SLC5A2 and chronic kidney disease: In contrast, a more recent meta-analysis that considered four CV outcome trials of T2DM cohorts, two trials of participants with chronic kidney disease, and four trials that enrolled individuals living with HF, and consequently included more Asian participant data, reported no significant difference in SGLT2 inhibitor-derived CV death/HF hospitalisations between the Asian and White European populations [26].